Mertz D P
Fortschr Med. 1981 Mar 19;99(11):394-8.
The efficacy and agreeability of a supportive drug therapy at doses of 300 mg of proquazone (Biarison) administered thrice daily was tested in an open study of 4 weeks' duration in 10 male patients suffering of clinically verified ankylosing spondylitis. The minimum duration of suffering was 15 years, the maximum 50 years. The major goal of therapy during clinical treatment was individually oriented physical therapy suited to the enhancement of residual mobility, removal of postural abnormalities and abnormalities of weight-loading as well as the maintenance of functionality for afflicted skeletal regions. In the course of this additional therapy with proquazone the functional index and activity index both displayed significant improvement (2 p less than 0.01), as compared with the control subjects. Improvement was attained as soon as 2 weeks following begin of therapy. In the course of treatment the following parameters also displayed significant improvement (2 p less than 0.05): morning stiffness, fatigue, patient's self-evaluation, Westergren one-hour-value, physician's over-all assessment, night pain, articular pain, thoracic and lumbar pain. There were only insignificant changes in other, regularly tested laboratory values during this drug therapy. No side effects or disagreeability signs of proquazone were noted. Proquazone can be recommended for the symptomatic additional treatment of patients suffering from ankylosing spondylitis.
在一项针对10名经临床确诊为强直性脊柱炎的男性患者开展的为期4周的开放性研究中，对每日三次服用300毫克丙氧苯酮（必来松）的支持性药物疗法的疗效和耐受性进行了测试。患病最短时长为15年，最长为50年。临床治疗期间的主要治疗目标是进行个性化的物理治疗，以增强残余活动能力、消除姿势异常和负重异常，并维持患病骨骼区域的功能。在使用丙氧苯酮进行这种辅助治疗的过程中，与对照组相比，功能指数和活动指数均显示出显著改善（P<0.01）。治疗开始后仅2周就取得了改善。在治疗过程中，以下参数也显示出显著改善（P<0.05）：晨僵、疲劳、患者自我评估、魏氏一小时血沉值、医生的总体评估、夜间疼痛、关节疼痛、胸腰椎疼痛。在这种药物治疗期间，其他常规检测的实验室值仅有不显著的变化。未观察到丙氧苯酮的副作用或不耐受迹象。丙氧苯酮可推荐用于强直性脊柱炎患者的症状性辅助治疗。
